查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968099

全球疫苗佐劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Vaccine Adjuvants Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 137 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計疫苗佐劑市場將從 2025 年的 41.2 億美元成長到 2034 年的 62.6 億美元，2026 年至 2034 年的複合年成長率為 4.77%。

全球疫苗佐劑市場正穩步成長，這主要得益於疫苗研發活動的增加以及需要增強免疫刺激的重組疫苗和次單位疫苗的日益普及。擴大免疫接種計畫和加強感染疾病疫情應對準備工作也進一步推動了市場需求。生物製藥領域的合作研究和公共衛生領域的資助舉措也在加速新型佐劑平台的創新，從而拓展商業機會並促進全球市場的持續成長。

關鍵促進因素包括：老年人和免疫力缺乏患者對疫苗效力的需求不斷提高；奈米顆粒和基於Toll樣受體（TLR）的佐劑技術不斷進步；以及監管機構對先進疫苗製劑的支持力度加大。應對疫情和治療性疫苗投入的增加進一步推高了需求。此外，安全性的提高和免疫反應持久性的增強也推動了佐劑在預防性和治療性疫苗研發管線中的廣泛應用。

由於製造商專注於複雜佐劑和精準的免疫調節策略，市場前景依然強勁。癌症疫苗、個人化免疫平台以及新興市場的拓展有望創造新的收入來源。大規模生產技術的進步和對免疫機制更深入的理解將強化商業化路徑，市場有望實現持續的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球疫苗佐劑市場：按類型分類

  • 市場分析、洞察與預測
  • 病原
  • 佐劑乳劑
  • 顆粒物
  • 組合
  • 其他

第5章：全球疫苗佐劑市場：依應用領域分類

  • 市場分析、洞察與預測
  • 感染疾病
  • 癌症
  • 其他

第6章：全球疫苗佐劑市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 皮內給藥
  • 鼻腔
  • 肌肉內注射
  • 其他

第7章 全球疫苗佐劑市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • GlaxoSmithKline Plc
    • Novavax Inc
    • Adjuvance Technologies Inc
    • SPI Pharma
    • Agenus Inc
    • CSL Limited
    • InvivoGen
    • Brenntag Biosector
簡介目錄
Product Code: VMR112110210

The Vaccine Adjuvants Market size is expected to reach USD 6.26 Billion in 2034 from USD 4.12 Billion (2025) growing at a CAGR of 4.77% during 2026-2034.

The Global Vaccine Adjuvants market has recorded steady growth driven by rising vaccine research and development activities and increasing adoption of recombinant and subunit vaccines that require enhanced immune stimulation. Expanding immunization programs, coupled with greater preparedness for infectious disease outbreaks, have strengthened demand. Biopharmaceutical collaborations and public health funding initiatives are also accelerating innovation in novel adjuvant platforms, contributing to expanding commercial opportunities and sustained global market expansion.

Key drivers include the need to improve vaccine efficacy in elderly and immunocompromised populations, technological advancements in nanoparticle and toll-like receptor-based adjuvants, and increasing regulatory support for advanced vaccine formulations. Growing investments in pandemic preparedness and therapeutic vaccines further reinforce demand. Moreover, enhanced safety profiles and improved immune response durability are encouraging wider integration of adjuvants across both preventive and therapeutic vaccine pipelines.

Future prospects remain strong as manufacturers focus on combination adjuvants and precision-based immune modulation strategies. Expansion into oncology vaccines, personalized immunization platforms, and emerging markets will generate additional revenue streams. Advancements in large-scale manufacturing and improved understanding of immune mechanisms are expected to strengthen commercialization pathways, positioning the market for sustained long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Pathogen
  • Adjuvant Emulsion
  • Particulate
  • Combination
  • Others

By Application

  • Infectious Diseases
  • Cancer
  • Others

By Administration

  • Oral
  • Intradermal
  • Intranasal
  • Intramuscular
  • Others

COMPANIES PROFILED

  • GlaxoSmithKline plc, Novavax Inc, Adjuvance Technologies Inc, SPI Pharma, Agenus Inc, CSL Limited, InvivoGen, Brenntag Biosector
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VACCINE ADJUVANTS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Pathogen Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Adjuvant Emulsion Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Particulate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Combination Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VACCINE ADJUVANTS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VACCINE ADJUVANTS MARKET: BY ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Intradermal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VACCINE ADJUVANTS MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By Administration
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VACCINE ADJUVANTS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 GlaxoSmithKline Plc
    • 9.2.2 Novavax Inc
    • 9.2.3 Adjuvance Technologies Inc
    • 9.2.4 SPI Pharma
    • 9.2.5 Agenus Inc
    • 9.2.6 CSL Limited
    • 9.2.7 InvivoGen
    • 9.2.8 Brenntag Biosector